Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 5 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Pharmaceutical Supply Chain in Europe - Introduction | 9 | 1 |
| Pharmaceutical Supply Chain in Europe - Overview | 10 | 4 |
| Introduction | 10 | 1 |
| Structure of Supply Chain - Channels of Distribution | 10 | 1 |
| Manufacturers - Pharmaceutical Companies | 11 | 1 |
| Wholesalers | 11 | 1 |
| Pharmacies | 11 | 1 |
| Parallel Traders | 12 | 1 |
| Evolution of Pharmaceutical Supply Chain in Europe | 12 | 1 |
| The Traditional method | 13 | 1 |
| Direct-to-Pharmacy (DTP) model | 13 | 1 |
| Pharmaceutical Supply Chain in Europe - Industry Dynamics | 14 | 15 |
| Introduction | 14 | 1 |
| Current Scenario | 14 | 1 |
| Breakdown of the Retail Price of a Medicine | 15 | 1 |
| Pharmaceutical Manufacturers | 16 | 1 |
| Label Supply Chain | 16 | 1 |
| Raw Material Supply Chain | 17 | 1 |
| Third Party Logistics (3PL) | 17 | 1 |
| Production Supply Chain | 17 | 1 |
| Distribution Supply Chain | 17 | 1 |
| Reversed Supply Chain | 17 | 1 |
| Profit % for Pharmaceutical Manufacturing Company | 18 | 1 |
| Wholesale Distributors | 19 | 1 |
| Current Scenario | 19 | 1 |
| Split of Turnover of Distribution Channels | 20 | 1 |
| Time of Delivery and Total Number of Deliveries per Week | 21 | 2 |
| Distribution Margin | 23 | 1 |
| Discounts | 23 | 1 |
| Pharmacies | 24 | 2 |
| Horizontal and Vertical Integration | 26 | 1 |
| Direct-to-Pharmacy (DTP) Distribution | 27 | 1 |
| The Impact of the Distribution Chain on Prices | 27 | 1 |
| Policies to Encourage Generic Pharmaceuticals | 28 | 1 |
| Pharmaceutical Supply Chain in Europe - Principles of Pharmaceutical Supply Chain Management | 29 | 4 |
| Management Systems | 30 | 1 |
| Commitment and Accountability | 30 | 1 |
| Legal and Customer Requirements | 30 | 1 |
| Risk Management | 30 | 1 |
| Documentation | 30 | 1 |
| Training and Competency | 30 | 1 |
| Continual Improvement | 30 | 1 |
| Ethics | 31 | 1 |
| Business Integrity and Fair Competition | 31 | 1 |
| Identification of Concerns | 31 | 1 |
| Animal Welfare | 31 | 1 |
| Privacy | 31 | 1 |
| Labor | 31 | 1 |
| Freely Chosen Employment | 31 | 1 |
| Child Labor and Young Workers | 31 | 1 |
| Non-Discrimination | 31 | 1 |
| Fair Treatment | 31 | 1 |
| Wages, Benefits and Working Hours | 31 | 1 |
| Freedom of Association | 31 | 1 |
| Health and Safety | 32 | 1 |
| Worker Protection | 32 | 1 |
| Process Safety | 32 | 1 |
| Emergency Preparedness and Response | 32 | 1 |
| Hazard Information | 32 | 1 |
| Environmental Protection | 32 | 1 |
| Environmental Authorizations | 32 | 1 |
| Waste and Emissions | 32 | 1 |
| Spills and Releases | 32 | 1 |
| Pharmaceutical Supply Chain Industry - Key Issues | 33 | 12 |
| Introduction | 33 | 1 |
| Parallel Trade | 33 | 1 |
| Percentage Share of Parallel Imports among EU Countries in Pharmacy Market Sales | 33 | 1 |
| Supply Quota Systems (SQS) | 34 | 1 |
| Dual pricing systems | 34 | 1 |
| Counterfeits | 35 | 1 |
| New Directive by EU Commission for Falsified Medicines | 36 | 1 |
| Difference in Price Regulation | 36 | 1 |
| Packaging Variations | 36 | 1 |
| Variation in Applicable VAT Rates | 37 | 1 |
| Difference in Registration Procedure | 37 | 1 |
| GSK- Case Study | 37 | 2 |
| Difference in Marketing Authorization | 39 | 1 |
| GSK- Case Study | 39 | 1 |
| Lag in Technological Adoption | 40 | 1 |
| GSK- Case Study | 40 | 1 |
| Specific Market Labeling | 41 | 1 |
| Repackaging and Relabeling of Products | 41 | 1 |
| EU Draft Guidelines on GDP in Europe | 42 | 1 |
| Introduction | 42 | 1 |
| Problem | 42 | 2 |
| Tendering | 44 | 1 |
| Disruption in Supply Chain- Case Study | 44 | 1 |
| Drug Shortages in Europe - The UK | 44 | 1 |
| Pharmaceutical Supply Chain in Europe - Strategies Shift in the Business Model | 45 | 13 |
| Introduction | 45 | 1 |
| Factors Leading to Changes in the Business Models of Pharmaceutical Companies in Mature Markets | 45 | 1 |
| Diminishing Revenues in Mature Markets Due to Patent Expiries of Blockbuster Drugs | 45 | 1 |
| Rising Competition in Mature Markets and Rapid Growth of Pharmaceutical Sales in Emerging Countries | 46 | 1 |
| Rising imports | 46 | 1 |
| Point of Delivery | 47 | 1 |
| Requirement of New Packaging Practices | 47 | 1 |
| Pricing Pressures | 47 | 1 |
| Patient Centric- B2C Supply Chain | 47 | 1 |
| Strategies to Evolve Supply Chains | 48 | 1 |
| Introduction | 48 | 1 |
| Entering Emerging Markets | 48 | 1 |
| Free Trade Agreements to Generate Cost Savings | 49 | 1 |
| Raw Material Procurement Strategies | 50 | 1 |
| Distribution Cost Reduction | 51 | 1 |
| Strategic Sourcing Models | 52 | 1 |
| Merck UPS Collaboration | 53 | 1 |
| Supply Chain Agility | 54 | 1 |
| Centralized Supply Chain and Local Logistics Presence | 55 | 1 |
| Examples of Change in Supply Chain Arrangements in the UK | 56 | 2 |
| Pharmaceutical Supply Chain In Europe - Risk Management | 58 | 4 |
| Market Risks | 58 | 1 |
| Economic Risks | 58 | 1 |
| Regulatory Risks | 58 | 1 |
| Specific Market Risks | 59 | 1 |
| Strategic Consolidations of Pharmaceutical Manufacturers | 59 | 1 |
| Exclusive Wholesale Distribution Model | 59 | 1 |
| Tougher Competition in Logistics | 59 | 1 |
| Removal of Pharmacy-Only Status | 59 | 1 |
| Corporate Strategy Risks | 59 | 1 |
| Operating Business Risks | 59 | 1 |
| Interruption of Operating Business | 59 | 1 |
| Counterfeit Pharmaceuticals | 59 | 1 |
| Dispensing Errors | 60 | 1 |
| Incorrect Handling of Medicines in the Logistics Chain | 60 | 1 |
| Financial Risks | 60 | 1 |
| Currency Risks | 60 | 1 |
| Risk of Default on Receivables | 60 | 1 |
| Liquidity and Financing Risks | 60 | 1 |
| Interest Rate Risks | 60 | 1 |
| Counterparty Risks from Derivatives | 61 | 1 |
| Measurement Risks | 61 | 1 |
| Information Technology (IT) Risks | 61 | 1 |
| Personnel Risks | 61 | 1 |
| Legal Risks | 61 | 1 |
| Pharmaceutical Supply Chain In Europe - Drivers and Restraints | 62 | 3 |
| Drivers | 62 | 1 |
| Free Trade Policy | 62 | 1 |
| DTP Model | 62 | 1 |
| Universal Health Care | 62 | 1 |
| New Directive on Counterfeit Medicines | 63 | 1 |
| Restraints | 63 | 1 |
| Parallel Imports | 63 | 1 |
| Differences in Price Regulation | 63 | 1 |
| Differences in Packaging Variations | 63 | 1 |
| Differences in VAT rates | 64 | 1 |
| Pharmaceutical Supply Chain In Europe - Company Profiles of Leading Wholesalers | 65 | 7 |
| Celesio Group | 65 | 1 |
| Pharmacy Solutions | 66 | 1 |
| Wholesale Business | 66 | 1 |
| Other business | 66 | 1 |
| Patient and Consumer Solutions | 67 | 1 |
| Pharmacy business | 67 | 1 |
| Other business | 67 | 1 |
| Manufacturer Solutions | 67 | 1 |
| Business Logistics Solutions | 67 | 1 |
| Business Marketing Solutions | 67 | 2 |
| Other Business | 69 | 1 |
| Alliance UniChem in Europe | 69 | 1 |
| Pharmaceutical Wholesaling and Distribution | 69 | 1 |
| PHOENIX Pharmaceutical Activities in Europe | 70 | 1 |
| Wholesale Business | 70 | 1 |
| Retailing | 70 | 1 |
| Supplier Services | 70 | 1 |
| Subsidiaries | 71 | 1 |
| Pharmaceutical Supply Chain Industry in Europe - Company Profiles of Leading Logistic Providers | 72 | 2 |
| UPS | 72 | 1 |
| DHL | 73 | 1 |
| Pharmaceutical Supply Chain in Europe - Appendix | 74 | 5 |
| Market Definitions | 74 | 1 |
| Abbreviations | 74 | 1 |
| Bibliography | 74 | 2 |
| Research Methodology | 76 | 3 |
| Coverage | 77 | 1 |
| Secondary Research | 77 | 1 |
| Primary Research | 77 | 1 |
| Expert Panel Validation | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 78 | 1 |